# Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

> **NCT06310915** · — · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIB/IV

## Interventions

- **DRUG:** Navelbine oral,Pembrolizumab

## Key facts

- **NCT ID:** NCT06310915
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-17
- **Primary completion:** 2025-03
- **Final completion:** 2025-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310915, "Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06310915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*